RT Journal Article
SR Electronic
T1 EarlyDetect: Development of tool for early detection of stomach adenocarcinoma based on blood-lipid profile as clinicopathological feature
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.14.23285899
DO 10.1101/2023.02.14.23285899
A1 Prakash, Om
A1 Khan, Feroz
YR 2023
UL http://medrxiv.org/content/early/2023/02/22/2023.02.14.23285899.abstract
AB Background Clinicopathological features are used for detection of diseases. Early detection of cancer can be significance for understanding the behavior of disease.Results We developed a tool to observe stomach adenocarcinoma in reference of blood-lipid profile. Background of the tool is based on the study made on RNAseq expression analysis of stomach adenocarcinoma. Raw data for study was collected as gene-expression profile from population of cancer-vs-normal. A series of studies performed including: differential gene expression analysis, plasma proteome mapping, extraction of gene-signature enriched with LSTM system model, AI-guided simulation of systems model of gene network, and AI-guided mapping with blood lipid profile to develop R-Shiny web-application.Conclusion ‘EarlyDetect’ is freely available at https://csir-icmr.shinyapps.io/EarlyDetect/. The tool can be utilized for (i) virtual observation of impact of different combinations of lipid profile in cancer progression; (ii) early detection of cancer state for new comer patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors are thankful to the Director, CSIR-Central Institute of Medicinal & Aromatic Plants (CIMAP), Lucknow, India for infrastructure & research facilities support. Author OP is thankful to the Indian Council of Medical Research (ICMR), New Delhi, India for financial support through RA fellowship (Award letter no. BMI/11(12)/2020, dated: 04/02/2021).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data are openly available in the public domain. https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga http://gepia2.cancer-pku.cn/#index https://www.cbioportal.org/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.